Novo Nordisk (NVO) financials

Pharmaceuticals · NYSE · Health Care

$40.00 +2.20% Close Oct 30, 2026 Live

Novo Nordisk revenue and earnings by year

Novo Nordisk's revenue was $48.6 billion in the fiscal year to December 31, 2025, up 20.0% from the year before. Net income was $16.1 billion, 33.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 13.3% a year on average.

RevenueNet income
$20.0B$40.0B
2016201720182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In billions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Revenue48.640.534.425.521.320.818.217.218.015.8
Revenue growth20.0%17.7%34.9%19.5%2.5%14.3%6.2%-4.8%13.8%—
Gross profit39.434.329.121.417.717.415.214.515.213.4
Gross margin81.0%84.7%84.6%83.9%83.2%83.5%83.5%84.2%84.2%84.6%
Operating income20.117.915.210.88.98.97.87.27.96.9
Operating margin41.3%44.2%44.2%42.3%41.7%42.6%43.0%42.2%43.8%43.3%
Net income16.114.112.48.07.26.95.85.96.15.4
Net margin33.1%34.8%36.0%31.4%33.9%33.2%31.9%34.5%34.1%33.9%
Diluted EPS$3.54$3.25$2.71$1.71$1.62$1.39$1.23$1.28$1.19$1.11
Free cash flow9.310.312.39.67.47.65.65.45.45.8

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open NVO in Markets.

See also: NVO valuation and P/E history · NVO returns

No forecast, no recommendation. This page describes Novo Nordisk from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.